First-Line T-DXd Nearly Doubles Progression-Free Survival in HER2-Mutant NSCLC
A phase III trial showed that starting treatment with trastuzumab deruxtecan instead of pembrolizumab plus chemotherapy extended median progression-free survival from 8.3 to 14.3 months in advanced HER2-mutant non-small cell lung cancer. However, an early overall survival trend favored the chemo arm, though subsequent HER2-directed therapies in that group may have skewed the analysis. The results establish T-DXd as a new first-line option, with the caveat that longer follow-up is needed.
The DESTINY-Lung04 trial enrolled only patients with HER2 exon 19 or 20 mutations, a molecularly defined subset of NSCLC. The 70% objective response rate with T-DXd and the 14.3-month median PFS represent a substantial advance over historical outcomes for this population, which previously had no dedicated targeted first-line option.
The survival analysis remains immature, with curves overlapping until roughly 24 months before diverging. More than twice as many patients in the pembrolizumab arm received subsequent HER2-directed therapy at progression, which may have influenced the OS hazard ratio of 1.15 favoring the chemo arm. The median OS of 29 to 33 months in both arms far exceeds historical benchmarks, reflecting broader treatment advances.
This trial could reshape first-line care for the small but clinically significant population of NSCLC patients with HER2 mutations, offering a targeted alternative to immunotherapy-based regimens. However, the early OS signal warrants caution; if longer follow-up confirms a survival disadvantage, clinicians may need to carefully sequence therapies rather than simply switch standards. Patients and oncologists will likely await mature survival data before fully embracing T-DXd as the default first-line choice, balancing its clear PFS benefit against unresolved questions about long-term outcomes.